CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Zytiga for Prostate Cancer – Details

Project Number PC0166-000
Brand Name Zytiga
Generic Name Abiraterone
Strength 250 mg & 500 mg
Tumour Type Genitourinary
Indication Prostate Cancer
Funding Request Newly diagnosed with metastatic prostate cancer without small-cell histologic features (may have received prior surgery or radiation therapy for local disease or palliative therapy); Less than 3 months of androgen deprivation therapy for metastatic disease (may have received prior adjuvant/neoadjuvant hormone therapy); Eligible for abiraterone therapy
Review Status Withdrawn
Clarification BC Cancer Agency has requested a voluntary withdrawal of the pCODR 10166 Abiraterone (Zytiga) for PC Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue the review as a PAG Submission.
Pre Noc Submission No
NOC Date February 15, 2018
Manufacturer Janssen Inc.
Sponsor BC Cancer Agency
Submission Date February 25, 2019
Submission Deemed Complete March 11, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ March 11, 2019
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.